Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results

Neurology

Volumn 54, Issue 9, 2000, Pages 1726-1733

  Noseworthy, John H ^a   Wolinsky, J S ^a   Lublin, F D ^a   Whitaker, J N ^a   Linde, A ^a   Gjorstrup, P ^a   Sullivan, H C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinical outcome measures; Linomide; MS; Randomized controlled trial

Indexed keywords

ROQUINIMEX;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT INDICATION;

EID: 0034624942     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.9.1726     Document Type: Article

References (36)

1. Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stalhandske T. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum 1986;29:1405-1409.
2. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 1994; 37:1195-1201.
3. Gross DJ, Weiss L, Reibstein I, et al. Amelioration of diabetes in non-obese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. Endocrinology 1998;139:2369-2374.
4. Karussis DM, Lehmann D, Brenner T, et al. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 1994;55:187-193.
5. Bai XF, Shi FD, Zhu J, Xiao BG, Hedlund G, Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J Neuroimmunol 1997;76:177-184.
6. Zhu J, Bai XF, Hedlund G, et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin Exp Immunol 1999;115:56-63.
7. Diab A, Michael L, Wahren B, et al. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol 1998;85: 146-154.
8. Karussis DM, Lehman D, Slavin S, et al. Inhibition of acute experimental autoimmune encephalitis by the synthetic immunomodulator linomide. Ann Neurol 1993;34:654-660.
9. Lehmann D, Karussis D, Mizrachi-Koll R, Linde AS, Abramsky O. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. Clin Immunol Immunopathol 1997;85:202-209.
10. Eralinna JP, Roytta M, Hukkanen V, Zinhu D, Salmi AA, Salonen R. Selective downregulation of Th1 response by linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J Neuroimmunol 1998; 88:165-176.
11. Karussis DM, Lehmann D, Slavin S, et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993; 90:6400-6404.
12. Zhu J, Diab A, Mustafa M, et al. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. J Neurol Sci 1998;160:113-120.
13. Larsson E, Joki A, Stalhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987;9:425-431.
14. Lehmann D, Karussis DM, Fluresco D, et al. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol 1997;74:102-110.
15. Kalland T, Aim G, Stalhandske T. Augmentation of mouse natural killer cell activity by LS 2616: a new immunomodulator. J Immunol 1985;134:3956-3961.
16. Ilback N, Fohlman J, Slorach S, Friman G. Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine coxsackievirus B3 myocarditis. J Immunol 1989;142: 3225-3228.
17. Arad G, Katzenellenbogen M, Levy R, Slavin S, Kaempfer R. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Int Immunol 1996;8:1603-1607.
18. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlund G, Martinez C, Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993;23:2372-2374.
19. Zhang GX, Yu LY, Shi FD, et al. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J Neuroimmunol 1997;73:175-182.
20. Tian WZ, Navikas V, Matusevicius D, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand 1998;98:94-101.
21. Xiao BG, Bail XF, Zhang GX, Hedlund G, Link H. Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Neurosci Lett 1998;249:17-20.
22. Karpati T, Karussis D, Abramsky O, Mizrahi-Koll R, Arbell I, Ovadia H. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol Lett 1998;63:141-145.
23. Redondo C, Flores I, Gonzalez A, et al. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invest 1996;98:1245-1252.
24. Hairing AC, Xu Z, Andersson G, Hedlund G. Linomide enhances apoptosis in CD4+CD8+ thymocytes. Scand J Immunol 1997;46:488-494.
25. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-1504.
26. Joseph IB, Isaacs JT. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 1996;29:183-190.
27. Parenti A, Donnini S, Morbidelli L, Granger HJ, Ziehe M. The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br J Pharmacol 1996;119:619-621.
28. Ziche M, Donnini S, Morbidelli L, Parenti A, Gasparini G, Ledda F. Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer 1998;77:1123-1129.
29. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996;47:895-900.
30. Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47:341-346.
31. Hohol M, Guttmann M, Cook S, et al. Roquinimex (linomide) treatment in secondary progressive and relapsing remitting multiple sclerosis: results from 48 week randomized, double-blind, placebo-controlled pilot studies. Neurology 1997;48: A174. Abstract.
32. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
33. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
34. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
35. Noseworthy J, O'Brien P, the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic Canadian Cooperative Trial of sulfasalazine in active multiple sclerosis. Neurology 1998;51:1342-1352.
36. Whitaker JH, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.